when two rare diseases meet atypical hemolytic uremic syndrome and alkaptonuria in two siblings

Original title: “When two rare diseases meet: atypical hemolytic uremic syndrome and alkaptonuria in two siblings.”

atypical hemolytic uremic syndrome in kidney transplantation

Original title: “Atypical hemolytic uremic syndrome in kidney transplantation.”

sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical haemolytic uremic syndrome

Original title: “Sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical Haemolytic Uremic Syndrome.”

complement mediated postpartum atypical hemolytic uremic syndrome with collapsing focal segmental glomerulosclerosis associated with a novel cfhr5 copy number variant

Original title: “Complement-Mediated Postpartum Atypical Hemolytic Uremic Syndrome With Collapsing Focal Segmental Glomerulosclerosis Associated With a Novel CFHR5 Copy Number Variant.”

using ddpcr to identify large deletions of complement factor h related genes in atypical hemolytic uremic syndrome

Original title: “Using ddPCR to Identify Large Deletions of Complement Factor H-Related Genes in Atypical Hemolytic Uremic Syndrome.”

systematic review of short term outcomes in patients with anti factor h associated atypical hus managed with plasma exchanges versus eculizumab

Original title: “A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.”

research gaps and priorities for ahus in the gulf cooperation countries gcc findings from a payer focused expert meeting

Original title: “Research Gaps and Priorities for aHUS in the Gulf Cooperation Countries (GCC): Findings from a Payer-Focused Expert Meeting.”

comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome a systematic review and meta analysis of real world data

Original title: “Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.”

Rare Disease Day 2026: Many Voices, One Global Movement Since 2015, the aHUS Alliance Global Action team has been right there alongside patients and caregivers—creating resources, sharing knowledge, and putting a spotlight on the issues that matter most to families navigating life with atypical ... Rare Disease Day 2026: Many Voices, One Global Movement Since 2015, the aHUS Alliance Global Action team has been right there alongside patients and caregivers—creating resources, sharing knowledge, and putting a spotlight on the issues that matter most to families navigating life with atypical hemolytic uremic syndrome (aHUS). Here’s the honest truth: for years, a small handful of dedicated volunteers have carried much of the weight of aHUS advocacy. They’ve given generously—their time, their creativity, their energy. And we’re deeply grateful for this international group of people, who are aHUS patients and family caregivers themselves. But the work is bigger than any one person or small group, and it’s vital to keep growing with new ideas and innovative efforts in order to meet aHUS challenges. To mark world Rare Disease Day 2026 we’ll break from our usual video project and try something new. This year, we’re inviting everyone—patients, caregivers, healthcare professionals, researchers, and supporters around the world—to step forward with your own projects and perspectives. Advocacy doesn’t require a camera, a stage, or a spotlight. Rare disease advocacy is not centered on personal storytelling – instead, it transforms our experiences into shared understanding, helping others recognize common challenges and the strength it takes to live with a rare condition. Launched in 2008 by EURORDIS, Rare Disease Day has grown into a truly global movement—one fueled by collaboration, compassion, and shared purpose. The aHUS Alliance is an informal umbrella group connecting aHUS advocates and patient organizations across more than 30 nations. Recognized as a charitable non-profit (legal registration No. 1167904), the aHUS Alliance Global Action team supports collective advocacy by creating articles, graphics, and educational materials that highlight key issues within the atypical HUS community.

Original title: “Rare Disease Day 2026: Many Voices, One Global Movement - aHUS Alliance Action”